A randomized, phase 2 study of R-CHOP plus enzastaurin vs R-CHOP in patients with intermediate- or high-risk diffuse large B-cell lymphoma

John D. HainsworthSarah Cannon Research Institute, Nashville, TN, USA;Tennessee Oncology, PLLC, Nashville, TN, USACorrespondence[email protected]

Edward R. ArrowsmithSarah Cannon Research Institute, Nashville, TN, USA;Tennessee Oncology, PLLC, Nashville, TN, USA

Michael McCleodSarah Cannon Research Institute, Nashville, TN, USA;Florida Cancer Specialists, Fort Myers, FL, USA

Eric D. HsiCleveland Clinic, Cleveland, OH, USA

Oday HamidEli Lilly and Company, Indianapolis, IN, USA

Peipei ShiEli Lilly and Company, Indianapolis, IN, USA

Boris K. LinEli Lilly and Company, Indianapolis, IN, USA

Luis E. FayadMD Anderson Cancer Center, Houston, TX, USA

show all

Click to increase image sizeClick to decrease image size

Potential conflict of interest

Disclosure forms provided by the authors are available with the full text of this article at www.informahealthcare.com/lal

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Order Reprints Request Corporate Permissions

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

Request Academic Permissions

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.

A randomized, phase 2 study of R-CHOP plus enzastaurin vs R-CHOP in patients with intermediate- or high-risk diffuse large B-cell lymphoma

Potential conflict of interest

Information for

Open access

Opportunities

Help and information

A randomized, phase 2 study of R-CHOP plus enzastaurin vs R-CHOP in patients with intermediate- or high-risk diffuse large B-cell lymphoma

Potential conflict of interest

Reprints and Corporate Permissions

Academic Permissions

Related research

To cite this article:

Download citation

Information for

Open access

Opportunities

Help and information

Keep up to date

Your download is now in progress and you may close this window

Login or register to access this feature